Abstract:Background: The programmed cell death ligand 1 (PD-L1) plays a key role in glioma development. However, due to the specificity of glioma's anatomical position, the role of its expression as a tumor biomarker is limited. It has been proven that the levels of soluble programmed death-ligand 1 (sPD-L1) are associated with prognosis in many malignancies including glioma. However, the expression of sPD-L1 in glioma patients receiving radiotherapy (RT) remains unclear. The purpose of this study was to evaluate the concentration of sPD-L1 in the plasma of glioma patients before and after RT and to explore its relationship with clinical outcomes.Methods: Between October 2017 and September 2018, glioma patients treated with RT (30 ± 10 Gy, 2 Gy/f) were enrolled, and blood samples were collected before and after RT. We quantified the sPD-L1 levels by enzyme-linked immunosorbent assay (ELISA). The isocitrate dehydrogenase-1 (IDH-1) mutational status and Ki-67 expression of tumors were evaluated by immunohistochemistry. Glioma murine model were used to address whether circulating sPD-L1 molecules are directly targeted by an anti-PD-L1 antibody. The associations between sPD-L1 and clinical features were assessed with Pearson's or Spearman's correlation analysis. The progression-free survival (PFS) and overall survival (OS) were determined by the Kaplan-Meier method.Results: Sixty glioma patients were included, with a median age of 52 years. The proportions of grade I, II, III, and IV gliomas were 6.7%, 23.3%, 28.4%, and 41.6%, respectively. The baseline sPD-L1 levels were significantly associated with tumor grade, IDH-1 mutation status and Ki-67 expression. Using 14.35 pg/ml as the cutoff, significantly worse PFS and OS were both observed in patients with higher baseline levels of sPD-L1 (P = 0.027 and 0.008, respectively). RT significantly increased the mean level of sPD-L1 (P < 0.001). Further analysis showed that the level of sPD-L1 in IDH-1 mutation patients was higher than that in wild-type patients. Furthermore, an analysis of glioma murine model indicated that anti-PD-L1 antibody combine with RT can be a potentially powerful cancer therapy.Conclusion: This study reported that sPD-L1 might be a potential biomarker to predict the outcome in glioma patients receiving RT. The elevated level of sPD-L1 after RT suggested that the strategy of a combination of immune checkpoint inhibitors and RT might be promising for glioma patients, especially for those with IDH-1 mutations.

Radiotherapy Upregulates Programmed Death Ligand-1 Through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.

Upregulation of Programmed Death Ligand-1 by Radiation Through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma

The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1

Role of GLUT-1 in the Upregulation of PD-L1 Expression after Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

Sensitization of Epidermal Growth Factor Receptor (EGFR) Inhibitors Induced by Radiotherapy Combined with Programmed Death Ligand-1 (PD-L1) Inhibitors

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

The Regulation Effect of EGFR Signaling Pathway on PD-L1 Expression on Esophageal Squamous Cell Carcinoma Cell Lines.

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation

Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review

LRIG 1 Enhances the Radiosensitivity of Radioresistant Human Glioblastoma U 251 Cells Via Attenuation of the EGFR / Akt Signaling Pathway

The Regulation Effect of EGFR Signaling Pathway on PD-L1 Expression on Esophageal Squamous Cell Carcinoma Cell Lines

The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression

Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients

PI3K/Akt and radioresistance of glioma

Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming

Radiation induces IRAK1 expression to promote radioresistance by suppressing autophagic cell death via decreasing the ubiquitination of PRDX1 in glioma cells

Silencing Platelet-Derived Growth Factor Receptor-Β Enhances the Radiosensitivity of C6 Glioma Cells in Vitro and in Vivo.

Effective Inhibition of Irradiation on Human Gliomas Growth in Vitro and in Vivo after Epidermal Growth Factor Receptor Silencing with Rna Interference

The EGFR Pathway is Involved in the Regulation of PD-L1 Expression Via the IL-6/JAK/STAT3 Signaling Pathway in EGFR-mutated Non-Small Cell Lung Cancer.